Inventia Healthcare Limited began a blood pressure medication recall on June 5, pulling Chlorthalidone Tablets USP, 25 mg from the market after the tablets failed dissolution specifications. The action covers more than 11,000 bottles distributed in the United States.
The recall includes 11,460 bottles, with 100-count and 1,000-count packages among the affected lots. Chlorthalidone is commonly prescribed to treat high blood pressure and fluid retention, so patients who rely on it have a practical question now: whether the tablets in their home supply are part of the recalled stock.
Rising Pharma Holdings Inc. distribution
The affected bottles were distributed in the United States by Rising Pharma Holdings Inc. of New Jersey. That distribution channel matters for anyone checking a pharmacy fill or a home medicine cabinet, because the recall is not limited to one store or one state.
Inventia Healthcare Limited initiated the recall voluntarily, and the tablets may not dissolve as intended in the body. In simple terms, dissolution is the step that lets a tablet break down after it is swallowed so the medicine can be absorbed; when that process falls short, the product may not perform as expected.
FDA review of Chlorthalidone Tablets USP
The FDA had not yet assigned a classification to the recall. That leaves the recall without the formal category that usually reflects how regulators rank the risk and the urgency of action.
No public press release had been issued at the time of the report, so patients were left with the product details rather than a broader public notice. The practical next step for anyone using Chlorthalidone Tablets USP, 25 mg is to check the bottle label against the recalled size and, if there is any match or doubt, speak with a pharmacist or healthcare provider.
Consumers should not stop taking prescribed medication without first speaking with a medical professional. For a blood pressure drug, that instruction is the most immediate safeguard while the recall moves through FDA review.
